Our top pick for
Building a portfolio
Innoviva, Inc is a biotechnology business based in the US. Innoviva shares (INVA) are listed on the NASDAQ and all prices are listed in US Dollars. Innoviva employs 5 staff and has a trailing 12-month revenue of around USD$322.3 million.
|Latest market close||USD$10.41|
|52-week range||USD$7.58 - USD$15.62|
|50-day moving average||USD$11.0326|
|200-day moving average||USD$11.9859|
|Wall St. target price||USD$10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.907|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||-19.11%|
|1 month (2020-12-24)||-15.64%|
|3 months (2020-10-23)||1.76%|
|6 months (2020-07-23)||-23.29%|
|1 year (2020-01-23)||-27.56%|
|2 years (2019-01-23)||-47.13%|
|3 years (2018-01-23)||15.68|
|5 years (2016-01-22)||4.41%|
Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Innoviva shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$310 million.
The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$322.3 million|
|Operating margin TTM||96.18%|
|Gross profit TTM||USD$261 million|
|Return on assets TTM||24.24%|
|Return on equity TTM||67.59%|
|Market capitalisation||USD$1.3 billion|
TTM: trailing 12 months
There are currently 9.4 million Innoviva shares held short by investors – that's known as Innoviva's "short interest". This figure is 1.8% down from 9.5 million last month.
There are a few different ways that this level of interest in shorting Innoviva shares can be evaluated.
Innoviva's "short interest ratio" (SIR) is the quantity of Innoviva shares currently shorted divided by the average quantity of Innoviva shares traded daily (recently around 697582.414307). Innoviva's SIR currently stands at 13.42. In other words for every 100,000 Innoviva shares traded daily on the market, roughly 13420 shares are currently held short.
However Innoviva's short interest can also be evaluated against the total number of Innoviva shares, or, against the total number of tradable Innoviva shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innoviva's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Innoviva shares in existence, roughly 90 shares are currently held short) or 0.1624% of the tradable shares (for every 100,000 tradable Innoviva shares, roughly 162 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Innoviva.
Find out more about how you can short Innoviva stock.
We're not expecting Innoviva to pay a dividend over the next 12 months.
Innoviva's shares were split on a 1241:1000 basis on 3 June 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.
Over the last 12 months, Innoviva's shares have ranged in value from as little as $7.58 up to $15.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.5633. This would suggest that Innoviva's shares are less volatile than average (for this exchange).
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.